http://www.fpnotebook.com/
Pyrazinamide
- Dosing
- Adult: 1.5-2.5 grams PO qd
- Pediatric: 15-30 mg/kg/day (Max 2g/day)
- Adverse Effects
- Hepatotoxicity
- Arthralgias
- Gastrointestinal upset
- Rash
- Hyperuricemia
- Monitoring
- Baseline
- Periodic testing
- Liver Function Tests repeated 1-2 times monthly if risks for hepatotoxicity
- Serum Uric Acid if symptoms related to gout
Pyrazinamide (C0034239) | |
|---|---|
| Definition (MSH) | A pyrazine that is used therapeutically as an antitubercular agent. |
| Definition (CSP) | antibacterial derived from nicotinic acid, used as a tuberculostatic. |
| Definition (NCI) | A synthetic pyrazinoic acid amide derivative with bactericidal property. Pyrazinamide is particularly active against slowly multiplying intracellular bacilli (unaffected by other drugs) by an unknown mechanism of action. Its bactericidal action is dependent upon the presence of bacterial pyrazinamidase, which removes the amide group to produce active pyrazinoic acid. Pyrazinamide is an important component of multidrug therapy for tuberculosis. (NCI04) |
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | D011718 |
| English | Pyrazinamide, PYRAZINAMIDE PREPARATION, Pyrazinecarboxamide, Pyrazinoic acid amide |
| Spanish | amida de acido pirazinoico, pirazinamida |
| Parent Concepts | pyrazine (C0178819), Pyrazines (C0034240), Antitubercular Agents (C0003448), [AM500] ANTITUBERCULARS (C0973481), Drug allergen (C1320237) |
| Sources | CSP, LNC, MSH, MTHSPL, NCI, NDFRT, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF Derived from the NIH UMLS (Unified Medical Language System) |
